Testosterone inhibits expression of lipogenic genes in visceral fat by an estrogen-dependent mechanism

Angelia Maleah Holland, Michael D. Roberts, Petey W. Mumford, C. Brooks Mobley, Wesley C. Kephart, Christine F. Conover, Luke A. Beggs, Alexander Balaez, Dana M. Otzel, Joshua F. Yarrow, Stephen E. Borst, Darren T. Beck

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The influence of the aromatase enzyme on the chronic fat-sparing effects of testosterone requires further elucidation. Our purpose was to determine whether chronic anastrozole (AN, an aromatase inhibitor) treatment alters testosteronemediated lipolytic/lipogenic gene expression in visceral fat. Tenmonth-old Fischer 344 rats (n=6/group) were subjected to sham surgery (SHAM), orchiectomy (ORX), ORX treatment with testosterone enanthate (TEST, 7.0 mg/wk), or ORX TEST AN (0.5 mg/day), with drug treatment beginning 14 days postsurgery. At day 42, ORX animals exhibited nearly undetectable serum testosterone and 29% higher retroperitoneal fat mass than SHAM animals (P 0.001). TEST produced a 380-415% higher serum testosterone than SHAM (P 0.001) and completely prevented ORX-induced visceral fat gain (P 0.001). Retroperitoneal fat was 21% and 16% lower in ORX TEST than SHAM (P 0.001) and ORX TEST AN (P=0.007) animals, while serum estradiol (E2) was 62% (P=0.024) and 87% (P=0.010) higher, respectively. ORX stimulated lipogenicrelated gene expression in visceral fat, demonstrated by 84-154% higher sterol regulatory element-binding protein-1 (SREBP-1, P=0.023), fatty acid synthase (P=0.01), and LPL (P 0.001) mRNA than SHAM animals, effects that were completely prevented in ORX TEST animals (P 0.01 vs. ORX for all). Fatty acid synthase (P=0.061, trend) and LPL (P=0.043) mRNA levels were lower in ORX TEST AN than ORX animals and not different from SHAM animals but remained higher than in ORX TEST animals (P 0.05). In contrast, the ORX-induced elevation in SREBP-1 mRNA was not prevented by TEST AN, with SREBP-1 expression remaining 117-171% higher than in SHAM and ORX TEST animals (P 0.01). Across groups, visceral fat mass and lipogenicrelated gene expression were negatively associated with serum testosterone, but not E2. Aromatase inhibition constrains testosteroneinduced visceral fat loss and the downregulation of key lipogenic genes at the mRNA level, indicating that E2 influences the visceral fat-sparing effects of testosterone.

Original languageEnglish (US)
Pages (from-to)792-805
Number of pages14
JournalJournal of Applied Physiology
Volume121
Issue number3
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Intra-Abdominal Fat
Testosterone
Estrogens
Gene Expression
Fatty Acid Synthases
Messenger RNA
Aromatase
Serum
Sterol Regulatory Element Binding Protein 1
Aromatase Inhibitors
Orchiectomy
Inbred F344 Rats
salicylhydroxamic acid
Estradiol
Down-Regulation
Fats
Enzymes

Keywords

  • Adipose
  • Androgen
  • Aromatase
  • Estrogen
  • Steroids

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Testosterone inhibits expression of lipogenic genes in visceral fat by an estrogen-dependent mechanism. / Holland, Angelia Maleah; Roberts, Michael D.; Mumford, Petey W.; Mobley, C. Brooks; Kephart, Wesley C.; Conover, Christine F.; Beggs, Luke A.; Balaez, Alexander; Otzel, Dana M.; Yarrow, Joshua F.; Borst, Stephen E.; Beck, Darren T.

In: Journal of Applied Physiology, Vol. 121, No. 3, 01.09.2016, p. 792-805.

Research output: Contribution to journalArticle

Holland, AM, Roberts, MD, Mumford, PW, Mobley, CB, Kephart, WC, Conover, CF, Beggs, LA, Balaez, A, Otzel, DM, Yarrow, JF, Borst, SE & Beck, DT 2016, 'Testosterone inhibits expression of lipogenic genes in visceral fat by an estrogen-dependent mechanism', Journal of Applied Physiology, vol. 121, no. 3, pp. 792-805. https://doi.org/10.1152/japplphysiol.00238.2016
Holland, Angelia Maleah ; Roberts, Michael D. ; Mumford, Petey W. ; Mobley, C. Brooks ; Kephart, Wesley C. ; Conover, Christine F. ; Beggs, Luke A. ; Balaez, Alexander ; Otzel, Dana M. ; Yarrow, Joshua F. ; Borst, Stephen E. ; Beck, Darren T. / Testosterone inhibits expression of lipogenic genes in visceral fat by an estrogen-dependent mechanism. In: Journal of Applied Physiology. 2016 ; Vol. 121, No. 3. pp. 792-805.
@article{d8a5515e6244432ab78da919ae9f5950,
title = "Testosterone inhibits expression of lipogenic genes in visceral fat by an estrogen-dependent mechanism",
abstract = "The influence of the aromatase enzyme on the chronic fat-sparing effects of testosterone requires further elucidation. Our purpose was to determine whether chronic anastrozole (AN, an aromatase inhibitor) treatment alters testosteronemediated lipolytic/lipogenic gene expression in visceral fat. Tenmonth-old Fischer 344 rats (n=6/group) were subjected to sham surgery (SHAM), orchiectomy (ORX), ORX treatment with testosterone enanthate (TEST, 7.0 mg/wk), or ORX TEST AN (0.5 mg/day), with drug treatment beginning 14 days postsurgery. At day 42, ORX animals exhibited nearly undetectable serum testosterone and 29{\%} higher retroperitoneal fat mass than SHAM animals (P 0.001). TEST produced a 380-415{\%} higher serum testosterone than SHAM (P 0.001) and completely prevented ORX-induced visceral fat gain (P 0.001). Retroperitoneal fat was 21{\%} and 16{\%} lower in ORX TEST than SHAM (P 0.001) and ORX TEST AN (P=0.007) animals, while serum estradiol (E2) was 62{\%} (P=0.024) and 87{\%} (P=0.010) higher, respectively. ORX stimulated lipogenicrelated gene expression in visceral fat, demonstrated by 84-154{\%} higher sterol regulatory element-binding protein-1 (SREBP-1, P=0.023), fatty acid synthase (P=0.01), and LPL (P 0.001) mRNA than SHAM animals, effects that were completely prevented in ORX TEST animals (P 0.01 vs. ORX for all). Fatty acid synthase (P=0.061, trend) and LPL (P=0.043) mRNA levels were lower in ORX TEST AN than ORX animals and not different from SHAM animals but remained higher than in ORX TEST animals (P 0.05). In contrast, the ORX-induced elevation in SREBP-1 mRNA was not prevented by TEST AN, with SREBP-1 expression remaining 117-171{\%} higher than in SHAM and ORX TEST animals (P 0.01). Across groups, visceral fat mass and lipogenicrelated gene expression were negatively associated with serum testosterone, but not E2. Aromatase inhibition constrains testosteroneinduced visceral fat loss and the downregulation of key lipogenic genes at the mRNA level, indicating that E2 influences the visceral fat-sparing effects of testosterone.",
keywords = "Adipose, Androgen, Aromatase, Estrogen, Steroids",
author = "Holland, {Angelia Maleah} and Roberts, {Michael D.} and Mumford, {Petey W.} and Mobley, {C. Brooks} and Kephart, {Wesley C.} and Conover, {Christine F.} and Beggs, {Luke A.} and Alexander Balaez and Otzel, {Dana M.} and Yarrow, {Joshua F.} and Borst, {Stephen E.} and Beck, {Darren T.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1152/japplphysiol.00238.2016",
language = "English (US)",
volume = "121",
pages = "792--805",
journal = "Journal of Applied Physiology Respiratory Environmental and Exercise Physiology",
issn = "8750-7587",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Testosterone inhibits expression of lipogenic genes in visceral fat by an estrogen-dependent mechanism

AU - Holland, Angelia Maleah

AU - Roberts, Michael D.

AU - Mumford, Petey W.

AU - Mobley, C. Brooks

AU - Kephart, Wesley C.

AU - Conover, Christine F.

AU - Beggs, Luke A.

AU - Balaez, Alexander

AU - Otzel, Dana M.

AU - Yarrow, Joshua F.

AU - Borst, Stephen E.

AU - Beck, Darren T.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The influence of the aromatase enzyme on the chronic fat-sparing effects of testosterone requires further elucidation. Our purpose was to determine whether chronic anastrozole (AN, an aromatase inhibitor) treatment alters testosteronemediated lipolytic/lipogenic gene expression in visceral fat. Tenmonth-old Fischer 344 rats (n=6/group) were subjected to sham surgery (SHAM), orchiectomy (ORX), ORX treatment with testosterone enanthate (TEST, 7.0 mg/wk), or ORX TEST AN (0.5 mg/day), with drug treatment beginning 14 days postsurgery. At day 42, ORX animals exhibited nearly undetectable serum testosterone and 29% higher retroperitoneal fat mass than SHAM animals (P 0.001). TEST produced a 380-415% higher serum testosterone than SHAM (P 0.001) and completely prevented ORX-induced visceral fat gain (P 0.001). Retroperitoneal fat was 21% and 16% lower in ORX TEST than SHAM (P 0.001) and ORX TEST AN (P=0.007) animals, while serum estradiol (E2) was 62% (P=0.024) and 87% (P=0.010) higher, respectively. ORX stimulated lipogenicrelated gene expression in visceral fat, demonstrated by 84-154% higher sterol regulatory element-binding protein-1 (SREBP-1, P=0.023), fatty acid synthase (P=0.01), and LPL (P 0.001) mRNA than SHAM animals, effects that were completely prevented in ORX TEST animals (P 0.01 vs. ORX for all). Fatty acid synthase (P=0.061, trend) and LPL (P=0.043) mRNA levels were lower in ORX TEST AN than ORX animals and not different from SHAM animals but remained higher than in ORX TEST animals (P 0.05). In contrast, the ORX-induced elevation in SREBP-1 mRNA was not prevented by TEST AN, with SREBP-1 expression remaining 117-171% higher than in SHAM and ORX TEST animals (P 0.01). Across groups, visceral fat mass and lipogenicrelated gene expression were negatively associated with serum testosterone, but not E2. Aromatase inhibition constrains testosteroneinduced visceral fat loss and the downregulation of key lipogenic genes at the mRNA level, indicating that E2 influences the visceral fat-sparing effects of testosterone.

AB - The influence of the aromatase enzyme on the chronic fat-sparing effects of testosterone requires further elucidation. Our purpose was to determine whether chronic anastrozole (AN, an aromatase inhibitor) treatment alters testosteronemediated lipolytic/lipogenic gene expression in visceral fat. Tenmonth-old Fischer 344 rats (n=6/group) were subjected to sham surgery (SHAM), orchiectomy (ORX), ORX treatment with testosterone enanthate (TEST, 7.0 mg/wk), or ORX TEST AN (0.5 mg/day), with drug treatment beginning 14 days postsurgery. At day 42, ORX animals exhibited nearly undetectable serum testosterone and 29% higher retroperitoneal fat mass than SHAM animals (P 0.001). TEST produced a 380-415% higher serum testosterone than SHAM (P 0.001) and completely prevented ORX-induced visceral fat gain (P 0.001). Retroperitoneal fat was 21% and 16% lower in ORX TEST than SHAM (P 0.001) and ORX TEST AN (P=0.007) animals, while serum estradiol (E2) was 62% (P=0.024) and 87% (P=0.010) higher, respectively. ORX stimulated lipogenicrelated gene expression in visceral fat, demonstrated by 84-154% higher sterol regulatory element-binding protein-1 (SREBP-1, P=0.023), fatty acid synthase (P=0.01), and LPL (P 0.001) mRNA than SHAM animals, effects that were completely prevented in ORX TEST animals (P 0.01 vs. ORX for all). Fatty acid synthase (P=0.061, trend) and LPL (P=0.043) mRNA levels were lower in ORX TEST AN than ORX animals and not different from SHAM animals but remained higher than in ORX TEST animals (P 0.05). In contrast, the ORX-induced elevation in SREBP-1 mRNA was not prevented by TEST AN, with SREBP-1 expression remaining 117-171% higher than in SHAM and ORX TEST animals (P 0.01). Across groups, visceral fat mass and lipogenicrelated gene expression were negatively associated with serum testosterone, but not E2. Aromatase inhibition constrains testosteroneinduced visceral fat loss and the downregulation of key lipogenic genes at the mRNA level, indicating that E2 influences the visceral fat-sparing effects of testosterone.

KW - Adipose

KW - Androgen

KW - Aromatase

KW - Estrogen

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=84988835588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988835588&partnerID=8YFLogxK

U2 - 10.1152/japplphysiol.00238.2016

DO - 10.1152/japplphysiol.00238.2016

M3 - Article

VL - 121

SP - 792

EP - 805

JO - Journal of Applied Physiology Respiratory Environmental and Exercise Physiology

JF - Journal of Applied Physiology Respiratory Environmental and Exercise Physiology

SN - 8750-7587

IS - 3

ER -